Literature DB >> 29708070

Drug-induced Cholestasis: Mechanisms, Models, and Markers.

Sagnik Chatterjee1, Pieter Annaert2.   

Abstract

BACKGROUND: Drug-induced cholestasis is a risk factor in the progression of drug candidates, and poses a serious health hazard if not detected before going into a human. Intrahepatic accumulation of Bile Acids (BAs) represents a characteristic phenomenon associated with drug-induced cholestasis.
METHODS: This review will discuss the current knowledge and knowledge gaps regarding drug-induced cholestasis, such as complexity of BA-mediated toxicity mechanisms, disconnect in signatures of toxicity between clinical and preclinical models, and the impact of bile acids at different 'targets' such as transporters, enzymes and nuclear receptors.
RESULTS: It is important to assess drug-induced cholestasis mechanisms in a physiologically relevant holistic in vitro system. Lack of sensitive and early preclinical biomarkers relevant to the clinical situation, complicates proper detection of drug-induced cholestasis. Significant overlap in biomarker signatures between different mechanisms of Drug-induced Liver Injury (DILI) precludes identification of specific mechanisms. Unavailability of suitable animal models predictive of the toxicity observed in human add to the lack of prediction of clinical drug-induced cholestasis.
CONCLUSION: Recent developments regarding BA-mediated inflammation as a trigger for toxicity significantly improved understanding of mechanisms of clinical drug-induced cholestasis. Increased insight into susceptibility factors in addition to Bile Salt Export Pump (BSEP) inhibition, biomarkers and involvement of immune system decreased knowledge gaps. Increased knowledge is assisting the development of the novel in vitro models providing a holistic understanding of processes underlying drug-induced cholestasis. This review summarizes the challenges and recent developments about drug-induced cholestasis with a potential path forward for informed decision-making during the drug development process. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Bile acids; biomarkers; cholestasis; drug-induced cholestasis; drug-induced liver injury; hepatocytes; in vitro models; inflammation.

Mesh:

Substances:

Year:  2018        PMID: 29708070     DOI: 10.2174/1389200219666180427165035

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  8 in total

Review 1.  Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Gene Expr       Date:  2019-06-28

2.  A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.

Authors:  Chunyan Wei; Ying Liu; Aidou Jiang; Bin Wu
Journal:  Int J Clin Pharm       Date:  2022-04-01

Review 3.  Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Authors:  Anna Zerdoug; Marc Le Vée; Shotaro Uehara; Béatrice Lopez; Christophe Chesné; Hiroshi Suemizu; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-06       Impact factor: 2.569

4.  Assessment of long-term functional maintenance of primary human hepatocytes to predict drug-induced hepatoxicity in vitro.

Authors:  Yi Chen; Dan Tang; Hongping Wu; Yuling Wu; Tianjie Yuan; Hongdan Zhang; Yingfu Jiao; Weifeng Yu; Hexin Yan
Journal:  Arch Toxicol       Date:  2021-04-14       Impact factor: 5.153

5.  Kuhuang injection exerts a protective effect by activating PPAR-γ in an in vitro model of chlorpromazine-induced cholestatic liver injury constructed by tissue engineering.

Authors:  Qiao Wu; Zhongping Duan; Long Huang; Zhijie Li
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

6.  Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice.

Authors:  Kai-Li Fu; Pan Chen; Yan-Ying Zhou; Yi-Ming Jiang; Yue Gao; Hui-Zhen Zhang; Li-Huan Guan; Cong-Hui Wang; Jun-Ling Liu; Min Huang; Hui-Chang Bi
Journal:  Acta Pharmacol Sin       Date:  2021-07-12       Impact factor: 6.150

7.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29

8.  Mechanism of Paeoniflorin in the Treatment of Bile Duct Ligation-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology.

Authors:  Shizhang Wei; Xiao Ma; Ming Niu; Ruilin Wang; Tao Yang; Dan Wang; Jianxia Wen; Haotian Li; Yanling Zhao
Journal:  Front Pharmacol       Date:  2020-10-20       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.